Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Anika Therapeutics (ANIK) Change in Intangibles (2024 - 2025)

Anika Therapeutics (ANIK) has disclosed Change in Intangibles for 2 consecutive years, with $600000.0 as the latest value for Q2 2025.

Quarterly Change in Intangibles changed N/A to $600000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $600000.0 for FY2025, 0.0% changed from the prior year.
Change in Intangibles for Q2 2025 was $600000.0 at Anika Therapeutics, roughly flat from $600000.0 in the prior quarter.
The five-year high for Change in Intangibles was $600000.0 in Q4 2024, with the low at $600000.0 in Q4 2024.